NCT04076293 - Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

November 10, 2020

Study Completion Date

May 3, 2021

Conditions

Pharmacology

Interventions

DRUG

HM15912

The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).

DRUG

Placebo

The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).

Trial Locations (1)

05505

Asan Medical Center, Seoul